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Tumors are known to be heterogeneous containing a dynamic mixture of phenotypically and functionally
different tumor cells. The two concepts attempting to explain the origin of intratumor heterogeneity are
the cancer stem cell hypothesis and the clonal evolution model. The stochastic model argues that tumors
are biologically homogenous and all cancer cells within the tumor have equal ability to propagate the
tumor growth depending on continuing mutations and selective pressure. By contrast, the stem cells
model suggests that cancer heterogeneity is due to the hierarchy that originates from a small population
of cancer stem cells (CSCs) which are biologically distinct from the bulk tumor and possesses self-
renewal, tumorigenic and multilineage potential. Although these two hypotheses have been discussed
for a long time as mutually exclusive explanations of tumor heterogeneity, they are easily reconciled
serving as a driving force of cancer evolution and diversity. Recent discovery of the cancer cell plasticity
and heterogeneity makes the CSC population a moving target that could be hard to track and eradicate.
Understanding the signaling mechanisms regulating CSCs during the course of cancer treatment can be
indispensable for the optimization of current treatment strategies.
 2013 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy
and Oncology 108 (2013) 378–387
Open access under CC BY-NC-ND license.Cancer stem cells (CSCs) have been identiﬁed as the major play-
ers for tumorigenesis, therapy resistance and metastasis [1–4].
Comparable to their normal counterparts, they possess the ability
to self-renew and to differentiate into all tumor cell subpopula-
tions to maintain the bulk tumor mass. This stem cell concept of
tumorigenesis was proven the ﬁrst time in 1994 by Dick and col-
leagues who demonstrated that only CD34+CD38 acute myeloid
leukemia (AML) cells are able to engraft immunodeﬁcient mice
and initiate leukemia. Furthermore, using an in vivo limiting dilu-
tion assay they found that only one out of one million leukemia
cells is a tumor-initiating cell, which they called AML CSC [5].
The CSC concept was applied the ﬁrst time to solid tumors in
2003 by Clarke and his colleagues. In this study they identiﬁed
CD44+CD24/low breast cancer CSCs as the only tumor-initiating
population that was able to generate new tumors by serial passag-
ing in immunodeﬁcient mice, while most of the other tumor cells
were unable to initiate tumor growth on their own [6]. During
the last years similar discoveries were made in other tumor typesincluding brain, colon and prostate as well as other types of cancer
as summarized in Table 1. Functional association of the CSC mark-
ers with signaling mechanisms governing CSC properties is impor-
tant for the development of novel targets for therapeutic
intervention, and many studies have been set up to ﬁll this gap
in our knowledge. The most investigated and functionally charac-
terized surface markers of human CSCs are listed in Table 1.
In many cases radiotherapy can completely destroy the tumor,
i.e. obtain local control. However, if the tumors are large or located
close to the critical normal tissue, local tumor control is often
impeded, resulting in tumor recurrence. The potential impact of
the number of CSCs within a given tumor on local tumor control
after radiotherapy was ﬁrst demonstrated by radiobiological stud-
ies more than 20 years ago, as described in the review of Baumann
et al. in this issue of Radiotherapy and Oncology journal. As sug-
gested by preclinical and clinical observations, the dose necessary
to completely destroy irradiated tumors increases for the large
tumors that can be explained by an increase in the absolute num-
ber of CSCs with increasing tumor size. The radiobiological studies
demonstrated that radioresistance of experimental tumors corre-
lates with their transplantability in vivo, which is deﬁned by the
tumor stem cell content. Moreover, based on the fact that some
tumor models with equal median transplantation dose (TD50)
show signiﬁcant discordance in median tumor control dose
Table 1
Cancer stem cell markers in common cancers.
CSC marker
Tumor type CD133 CD44 ALDH1 a2b1 integrin a6 integrin CD24 References
Glioma + + + [119–123]
Breast cancer + + + + - [6,124–126]
Colon cancer + + + + [127–131]
HNSCC + + [21,132]
Prostate cancer + + + + [133–136]
Protein
family
Transmembrane
glycoproteins
Transmembrane
glycoprotein, hyaluronic
acid receptor
Aldehyde
dehydrogenase
Heterodimeric
transmembrane
glycoprotein receptors
Heterodimeric
transmembrane
glycoprotein receptors
Transmembrane
glycoprotein
Function
in CSC
Endocytosis, co-
regulation of
growth factors,
PI3K pathway
activation, self-
renewal
Adhesion, co-regulation of
growth factors EMT,
STAT3 signaling
activation, migration,
drug resistance, self-
renewal
Aldehyde
detoxiﬁcation,
drug
resistance,
oxidative
stress response
ECM interaction, cell–cell
interaction, cytoskeletal
rearrangement, co-
regulation of growth
factors, signal
transduction
ECM interaction, cell–cell
interaction, cytoskeletal
rearrangement, co-
regulation of growth
factors, Signal
transduction
Adhesion, migration,
invasion, CXCR4
signaling, DNA damage-
induced nuclear factor-
kappaB (NF-kB) signaling
References [137–140] [141–145] [146] [147] [147] [148–150]
C. Peitzsch et al. / Radiotherapy and Oncology 108 (2013) 378–387 379(TCD50) values, not only the absolute number of CSCs, but also their
intrinsic radiosensitivity might play a role in local tumor control
after irradiation [7–10].
In the early 1990s, a few translational studies demonstrated
that clonogenic ex vivo assays based on the pretreated tumor biop-
sies may predict clinical outcome for patients treated with radio-
therapy [11–13]. However, these ﬁndings were challenged in a
number of other studies [14–19]. This controversy of the ex vivo
data could be explained by the lack of the extrinsic stimuli coming
from the CSC niche and regulating CSC properties in vivo.
Since then a growing body of in vitro experimental evidence
demonstrated that CSCs isolated from the established cell lines
and tumor specimens can be protected from the treatment modal-
ities by multiple intrinsic and extrinsic mechanisms, such as resis-
tance to the oxidative DNA damage, enhanced DNA repair,
activation of the anti-apoptotic signaling pathways and by the
tumor microenvironment, as summarized in Table 2.
Retrospective clinical studies for the different types of cancer
have shown that analysis of CSC-speciﬁc markers in pre-therapeu-
tic biopsies might be an important tool for the prediction of clinical
outcome and appropriate treatment selection, as described in
detail in the review of Baumann et al. in this issue of Radiotherapy
and Oncology journal.
However, it has not yet been proven directly that clonogens,
which determine tumor recurrence after radiotherapy are the same
as the cells with the CSC phenotype. To ﬁll this gap between the
cell-based experimental data and clinical observations, in vivo
radiobiological assays are needed to be established where tumor
control probabilities after different radiation doses are analyzedTable 2
Intrinsic and extrinsic determinants of cancer stem cell radioresistance.
Molecular determinants
of radioresistance
Mechanism
Intrinsic determinants Enchased DNA repair capability through ATM
and CHK1/CHK2 phosphorylation
Protection from oxidative DNA damage
by enhanced ROS scavenging
Activation of the cell survival pathways,
including PI3K/Akt, WNT/b-catenin, notch
signaling pathways
Extrinsic determinant Hypoxic environment
Growth factors and cytokinesin parallel with the frequency of tumorigenic CSCs deﬁned by
speciﬁc phenotypic markers and functional features, including
tumorigenicity, self-renewal and differentiation potential.
However, it may be complicated by the fact that the phenotypical
and functional properties of CSCs may be dynamically regulated
during the course of radiotherapy. Understanding the complex
mechanisms regulating CSC population during the course of cancer
treatment will turn CSCs into a powerful tool for therapeutic and
diagnostics improvement.
Strategies to identify cancer stem cell regulators andmarkers of
radioresistance
The CSC hypothesis provides a strong clinical rationale for the
identiﬁcation of CSC speciﬁc antigens to develop new predictive
biomarkers and therapeutic strategies. However, despite that a
large number of CSC markers have been characterized during the
last decades, only a few CSC-related antigens were validated in a
clinical setting. This could be due to the high heterogeneity of
CSC populations and lack of CSC markers with a high level of spec-
iﬁcity. Nevertheless, despite the high inter-tumor heterogeneity of
CSC marker expression, the current ﬁndings suggest that analysis
of the number of CSCs in pre-therapeutic biopsies might be impor-
tant for the prediction of tumor radiocurability, estimation of the
total radiation dose required, and the selection of the optimal ther-
apeutic strategy [3,4].
In the search for novel CSC-speciﬁc predictive biomarkers, high
throughput technologies, such asDNAmicroarray,mass-spectrome-
try based proteomics and high-throughput genetic screening haveCSC population References
& CD44+/CD24/low human breast cancer
& CD133+ human glioma
& CD29high/CD24high mouse mammary tumor
[60,61,151–153]
& CD44+/CD24/low human breast caner
& Thy1+CD24+ mouse mammary tumor
& CD44+ human gastric cancer
[154,155]
& CD133+ human glioma
& CD29high/CD24high mouse mammary tumor
[156,157]
& CD133+/nestin+ human medulloblastoma
& CD133+ human glioma
& Nestin+, CD15+ human glioma
[158,159,105,160]
& CD133+ human glioma
& Glioblastoma stem cells enriched in neurospheres
[161,162]
380 Discovery of cancer stem cell radioresistancebecome an area of increasing interest in a radiation oncology setting.
Such high throughput in vitro assays in conjunction with bioinfor-
matics methods for data handling and analysis allow to analyze
thousands of biological molecules simultaneously under standard-
ized conditions and usually produce a list of candidate biomarkers,
which need to be carefully validated using preclinical in vivo radiobi-
ological experiments and large-scale analysis of clinical specimens.
High density oligonucleotide arrays offer the opportunity to
examine patterns of gene expression in CSC on a genome scale
and compare it to the transcriptome of normal stem cell popula-
tion. For example, Liu et al. reported a 186-gene ‘‘invasiveness’’
gene signature (IGS) that discriminates between normal breast epi-
thelium and breast CSCs characterized by CD44+/CD24/low pheno-
type. This signature is associated with overall survival and
metastasis-free survival in patients with breast cancer, and can
be also applied to discriminate low- and high-risk patients with
medulloblastoma, lung and prostate cancers indicating that a gen-
eralized list of ‘‘stemness’’ genes can serve as a useful prognostic
tool for many types of tumors [20].
To perform CSC-based proﬁling in the context of radioresis-
tance, Chen and colleagues have gauged the genomic traits of radi-
oresistant cancer progenitors isolated from head and neck
squamous cell carcinoma (HNSCC) tumors deﬁned by high alde-Fig. 1. TGFß signaling is similarly overrepresented in radioresistant and tumor progenit
cell surface receptors having intrinsic serine/threonine kinase activity. The activated TG
form complexes with Smad4 and activate the transcriptional programs regulating multip
To better understand the biological pathways underlying the properties of radioresista
proﬁling of the parental and radioresistant prostate cancer DU145 cells, ALDH+ and ALD
under adherent condition and tumorsphere-forming conditions. TGFß signaling was o
regulated between DU145 and radioresistant (RR) DU145 cells, between DU145 tumors
populations. The overrepresentation analysis shows statistically signiﬁcant deviation o
number) from the number of genes expected under random sampling conditions (expecte
of cancer cells can be governed by the overlapping molecular mechanisms. To develop t
multiple X-ray doses of 4 Gy given once a week (40 Gy total dose). The surviving cells show
(C) List of the TGFß pathway genes according to KEGG (Kyoto Encyclopedia of Genes a
radiosensitive DU145 cells. (D) Smad3 protein is detected in the nuclear fraction and hig
parental DU145 cells.hyde dehydrogenase 1 (ALDH1) activity. Gene expression micro-
array analysis demonstrated that the epithelial-mesenchymal
transition (EMT) pathway and EMT-related genes were signiﬁ-
cantly up-regulated in ALDH1+ HNSCC cells. Moreover, this study
showed that the increased incidence of ALDH1 expression posi-
tively correlates with the clinical stage of HNSCC patients. These
data demonstrated that metastatic potential can be partially due
to a speciﬁc radioresistant subpopulation of CSCs [21]. This ﬁnding
was later supported by the work of Mihatsch et al., who demon-
strated that ALDH1 activity is indicative of subpopulations of lung
and breast cancer cells with increased radioresistance [22].
Our studies employing the comparative gene expression proﬁl-
ing revealed the transforming growth factor b (TGFb) signaling as
one of the few pathways overrepresented among the genes that
are differentially regulated between the parental radiosensitive
(RS) prostate cancer cells DU145 and its radioresistant (RR) deriv-
ative cell line DU145 as well as between ALDH+ progenitor cells
and ALDH cell populations. This ﬁnding suggests that radioresis-
tant and tumorigenic characteristics of cancer cells can be gov-
erned by the overlapping molecular mechanisms (Fig. 1).
Although the level of gene expression underlies many altera-
tions during signal transduction, its effects on CSC physiology
might be more completely understood at the level of proteinor population. (A) TGFß initiates its cellular response by binding and activating the
F-b receptors stimulate the phosphorylation of Smad3 and Smad2 proteins, which
le cellular functions, including self-renewal, tumorigenicity and radioresistance. (B)
nt and tumorigenic cell populations, we performed comparative gene expression
H cell populations isolated from the DU145 cancer cell line, and the cells grown
ne of the few pathways overrepresented among the genes that are differentially
pheres and DU145 monolayer cultures as well as between ALDH+ and ALDH cell
f the observed number of genes associated with TGFß signaling pathway (actual
d number). This ﬁnding suggests that radioresistant and tumorigenic characteristics
he radioresistant subline RR DU145, prostate cancer DU145 cells were treated with
ed enhanced radioresistance in 2D clonogenic radiobiological assay; ⁄p value <0.05.
nd Genomes) database, which are differentially regulated in the radioresistant and
hly expressed in the radioresistant DU145 cells compared with more radiosensitive
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interactome study suggested that protein interactome pattern
regulates a balance between self-renewal and differentiation in
glioblastoma. Facchino et al. have shown that the polycomb group
protein BMI1 is enriched in CD133 positive glioblastoma stem cells
and operates as a recruitment platform for the double strand break
repair (DSB) response and non-homologous end joining (NHEJ)
proteins resulting in increased cell radioresistance [23].
Moreover, the properties of CSCs can be regulated not only by
gene expression or by the level of protein expression that does
not necessarily reﬂect protein activity, but also via post-transla-
tional modiﬁcations regulating protein function, of which
phosphorylation is one of the most prominent. A study of Nilsson
et al. documented the changes occurring in phosphoproteome of
glioblastoma progenitors upon treatment with a JAK/STAT
inhibitor, stimulation with interleukin-6 (IL-6) and under hypoxia
conditions [24]. This study demonstrates the power of phospho-
proteomics for the analysis of treatment-induced changes of sig-
naling pathways and interconnections between signaling
pathways in a robust and comprehensive manner.
The recent discovery of microRNAs (miRNAs) has added an
entirely new dimension to our knowledge about the regulation of
gene expression and the control of various cell functions, such as
apoptosis, proliferation, differentiation and therapy resistance.
The miRNAs are regulatory, non-coding RNAs about 22 nucleotides
in length which regulate the expression of a variety of genes by tar-
geting mRNA transcripts. Over the past decade, it has become pro-
gressively clearer that these tiny genetic regulators are linked to
the development of cancer. The miRNA proﬁles have been shown
to be highly informative, reﬂecting the developmental history
and differentiation state of the tumors, and providing molecular
links between cancer and normal stem cells [25,26]. The fact that
miRNAs expression may have adverse consequences for the func-
tional properties of cancer cells has been recently highlighted for
tumor radioresistance. Yan and coworkers for the ﬁrst time dem-
onstrated that miRNAs could be used to target the DNA repair
machinery and thus sensitize tumor cells to radiation [27]. Since
then, an accumulating body of research demonstrated that miRNAs
can modulate tumor radioresistance [28–31]. In vivo experiments
using xenograft models and clinical studies are needed to ascertain
whether manipulation of miRNA expression can be a viable tool to
augment current cancer therapies [32].
Emerging high throughput screening (HTS) technologies
employing cell-based phenotypic assays and pathway-based
readouts expand our knowledge regarding the role of genes and
proteins in the regulation of CSC properties. To provide compre-
hensive large-scale genetic screens for speciﬁc changes of cell phe-
notypes, the RNA interference (RNAi) technique can be successfully
employed. The development of RNAi techniques for gene silencing
allows for systematic gene and pathway analysis in tumor cells to
explore novel gene functions and signaling pathways that cannot
always be identiﬁed by ectopic gene expression [33].
While such genetic screens provide important information
about which genes are related to a given phenotype, molecular
pharmacology can play an important role in the development of
CSC-speciﬁc chemical therapy. The HTS of the small molecule
libraries have yielded many useful ‘‘tool’’ small molecules regulat-
ing important features of cancer cells including stemness, invasive-
ness and resistance to therapy [34–37]. Moreover, biological
molecules interacting with chemical compounds can potentially
serve both as therapeutic targets and biomarkers. For example, a
recent study of Sachlos et al. utilized a small molecule screen to
identify compounds that impair leukemic stem cells while having
no effect on normal blood stem cells. In this study a self-renewing
state of human neoplastic and normal pluripotent stem cells
(hPSC) was monitored by the expression of master pluripotencytranscription factors Oct4 and Sox2. Using a library of 590 known
compounds that induce differentiation, Sachlos et al. identiﬁed
the small molecules thioridazine and meﬂoquine as the most effec-
tive regulators of pluripotency and validated these candidate com-
pounds by using neoplastic hPSC and somatic leukemia stem cells
from patients. The drug thioridazine antagonizes dopamine recep-
tors that are expressed on leukemia stem cells as well as on breast
cancer cells. These results can suggest that dopamine receptors
may serve as a biomarker for diverse malignancies [38].
The HTS strategies are being widely introduced to experimental
radiotherapy. The studies of chemical and biological radiosensitiz-
ers employed various approach to HTS, including analysis of c-
H2A.X kinetics, cell proliferation and viability [35–37]. These stud-
ies revealed a number of promising candidates involved in the reg-
ulation of DNA repair, ROS production and apoptosis. However, the
speciﬁcity, toxicity and efﬁcacy of these radiosensitizers still need
to be determined in future preclinical studies. It is important to
identify molecular pathways that are distinctively different
between CSCs and normal stem cells so that radiosensitizing
agents can speciﬁcally target CSCs without causing a signiﬁcant
effect on normal stem cells. However, the HTS for the selective reg-
ulators of CSCs radiocurability has not been reported yet.
Nevertheless, a large number of studies were performed in the
last few years to systematically identify genes or small molecules
regulating CSC death and differentiation. However, their value for
the enhancement of tumor radiocurability warrants further inves-
tigation. These studies employed screening of RNAi or chemical
libraries with various readouts such as cell viability, reporter
assays utilizing luminescence of ﬂuorescence-based analysis of
gene or pathway activation, and image-based analysis allowing
the capture of multiple parameters at the single cell level.
In contrast to the radiobiological studies employing the clono-
genic survival assays, cell viability assays have proven to be a fast
and reliable readout in cell-based chemical screenings. Gupta and
coauthors enriched CD44+CD24/low tumor progenitor population
in a breast cancer cell line by inducing EMT upon the inhibition
of the human E-cadherin gene CDH1. This study employed cell via-
bility assay to screen a compound library in the modiﬁed and
parental cell lines, and identiﬁed the monocarboxylic polyether
antibiotic salinomycin as a selective inhibitor of the breast cancer
progenitor population [34].
The reporter construct which transcription is speciﬁc for CSCs is
an important tool to identify and monitor the CSC population. This
reporter contains luciferase or green ﬂuorescent protein (GFP) gene
under control of a certain promoter that is activated in CSCs. After
integration into the genome of the host cells upon transduction or
stable transfection, this reporter system allows to analyze the
expression from CSC-speciﬁc promoters. Thus, individual CSCs
can be monitored based on their selective expression of the label
such as luciferase or GFP [39]. A recent study employed high con-
tent screening to identify chemical modulators of the progenitor
population in luminal breast cancer cells using a CK5 promoter-
driven GFP reporter [40]. In another study mentioned above, plu-
ripotent state of hPSC was monitored by the expression of the
GFP gene driven by Oct4 and Sox2 promoters [38].
An alternative method for the identiﬁcation of radioresistant
cell population with increased self-renewal capacity was proposed
by Pajonk et al. [41,42]. They identiﬁed and characterized a small
population of glioblastoma, breast and prostate cancer cells with
intrinsically low 26S proteasome activity and stem cell properties,
including self-renewal and tumorigenic capacity. This tumor-initi-
ating population is resistant to proteasome inhibition and might
explain the failure of the clinical trial the proteasome inhibitor
bortezomib. The cell population with low 26S proteasome activity
was tracked in vitro and in animal models using the proteasome
function reporter system where the C-terminal degron of the mur-
382 Discovery of cancer stem cell radioresistanceine ornithine decarboxylase (cODC) was fused to ZsGreen green
ﬂuorescent protein. The daily fractionated irradiation (5  3 Gy of
Cobalt-60 c-ray) resulted in the increase in ZsGreen-positive cell
population in vitro and in vivo suggesting that low 26S proteasome
activity is indicative of radopresistant tumorigenic cell fraction. If
future studies will conﬁrm an existence of this population in clin-
ical samples, ZsGreen-cODC reporter construct can be a useful tool
for the screening of molecular regulators affecting tumorigenic and
radioresistant cell population.
Recent advances in high-content imaging technologies sup-
ported by high-performance computing have enabled rapid
advances in the development of high-throughput image-based
assays. Direct visualization of the cellular phenotype permits more
comprehensive measurements of the responses to perturbations.
The measurements can be performed speciﬁcally on single cells
of interest. Xia and coauthors developed a new assay to identify
and analyze high drug efﬂux cells possessing CSC properties based
on ﬂuorescence images [43]. Using this system, Xia and coauthors
screened a library of pharmacologically active compounds for their
effect on the high drug efﬂux cells in lung cancer. The screening
successfully identiﬁed compounds, which reduce the drug efﬂux
capability of lung cancer cells. Wurdak et al. described an interest-
ing approach to monitor the differentiation of brain tumor-initiat-
ing cells by automated image analysis, which they called ‘‘cell
dispersion’’ phenotype that was used as a readout in a kinome-
wide RNA interference screen to identify genes that control self-
renewal and tumorigenicity of brain tumor-initiating cells [44].
It can be hypothesized that quiescence or slow cycling state of
CSC is associated with relative radioresistance. As it was demon-
strated by Pece and coworkers, breast cancer stem cells retain
the lipophilic ﬂuorescent dye PKH26 as a consequence of their qui-
escent nature [45]. A study of Wang et al. demonstrated that
PKH26+ nasopharyngeal cancer cells are highly clonogenic, spher-
ogenic and radioresistant [46]. These ﬁndings suggest that PKH26
dye can be a useful tool for the discovery of new regulators of
stemness and radioresistance.
The traditional screening platforms are typically limited to two-
dimensional (2D) cultures, which very roughly resemble the envi-
ronment that tumor cells experience in living tissues and exclude
the inﬂuence of cell–cell interaction, extracellular matrix (ECM)
and stromal components. In contrast, three dimensional (3D) cul-
ture models providing direct interactions between cells, as well
as between cells and the ECM proteins, can lead to an increase in
CSC properties of the cultured cells, including cell self-renewal,
migration, release of endocrine and paracrine factors regulating
tumor development and angiogenesis, formation of hypoxic niches
and therapy resistance [47–52]. 3D sphere forming conditions are
particularly useful to enrich the CSC and radioresistant cell subsets
(Fig. 2), especially when speciﬁc markers for these populations are
not well understood. Sphere culture conditions are providing the
foundation to develop marker-independent HTS assay with patient
derived CSCs which may have high phenotypical heterogeneity.
Moreover, sphere forming conditions might more accurately reﬂect
in vivo mechanisms of action of the treatment modalities as it was
demonstrated in the recent chemical screening of primary glioblas-
toma cell cultures [53,54].
In summary, genomics, proteomics and screening technologies
are expected to provide us with information about new CSC-asso-
ciated biomarkers, therapeutic targets and potential drugs that
could speciﬁcally target CSCs or induce their differentiation. Fur-
ther validation studies applying radiobiological assays combined
with functional stem cell analysis will assess the role of the iden-
tiﬁed biological molecules and chemical drugs in the regulation
of tumor radiosensitivity. To ﬁll the gap between the radiobiolog-
ical experiments and clinical practice, it is necessary to perform a
large-scale analysis of the clinical specimens for the associationof CSC biomarkers with the tumor grade, stage, and prognosis. A
better understanding of the molecular mechanisms underlying
CSC pathology as well as thorough clinical evaluation of the drug
and marker candidates will be essential in the development of
CSC-based anti-cancer therapies.
CSC: a ﬂexible target?
There is emerging evidence that adult and embryonic stem cells
are heterogeneous and consist of distinct subpopulations that exhi-
bit distinct phenotype, self-renewal and differentiation biases [55].
Similar functional and phenotypical heterogeneity was also
observed in CSCs. It was hypothesized that many types of tumors
contain multiple cell lineages and each of these lineages can arise
both from neoplastic transformation of the normal stem cell as
well as from more differentiated progenitors by a process of multi-
step clonal evolution [56–58]. In addition to the intratumor heter-
ogeneity, it is becoming increasingly clear that CSC subsets can
vary from patient to patient due to differences in individual genetic
and epigenetic makeups [59].
These recent ﬁndings may explain why the experimental data
depending on selected CSC marker may lead to contradictory
results. For example, Bao et al. demonstrated more efﬁcient DNA
repair in CD133+ progenitor glioma cells. However, this observa-
tion was challenged by Ropolo et al. who showed that neither
DNA base excision or single-strand break repair nor resolving of
c-H2A.X nuclear foci were changed in CD133+ compared to
CD133 cells [60,61]. In another study of tumor-initiating cells in
ovarian cancer, Stewart et al. demonstrated that CD133 marked
all cancer progenitor cells in several cancer specimens. However,
in other cases, tumor initiating population was found in both the
CD133+ and CD133 cell fractions [62].
Deep-sequencing technologies have enabled to reveal the phy-
logenetic history of the cells within an individual tumor and dem-
onstrated that almost all tumors contain multiple clones which
correspond to the distinct CSC lineages that co-exist within the
tumor and contribute to intra-tumor heterogeneity [63–66]. The
tumor cells within single genetic clone display inherent functional
diversity in their repopulation potential and therapy resistance
[67]. The possible relationship between distinct clones within an
individual tumor warrant further investigation.
Recent studies in breast tumors and gliomas demonstrated that
various extrinsic stressors, including hypoxia, inﬂammation and
anti-cancer therapy, or (and) intrinsic mechanisms, such as activa-
tion of developmental pathways, can trigger cancer cell repro-
gramming and change their self-renewal and differentiation
potency. For instance, hypoxia which may keep CSCs in a quiescent
state could play an important role at the initial stage of radiother-
apy followed by re-oxigenation during tumor eradication and
recruitment of CSCs into the proliferation pool. An accelerated
repopulation of tumor cells is one of the major reasons for the fail-
ure of conventional radiotherapy as discussed in [68] and in the
review of Baumann et al. in this issue of Radiotherapy and Oncol-
ogy journal.
In addition to oxygen tension, other microenvironment inﬂu-
ences, such as cytokines, interleukins and growth factors might
regulate the proliferative status of CSC. Similar to the normal stem
cells, CSCs may undergo a switch from asymmetric to symmetric
cell division becoming a mitotically active cell population after
ionizing radiation, employing the activation of the developmental
signaling pathways, like the Notch, WNT and Sonic hedgehog path-
ways [3,69]. In addition, irradiated tumor ﬁbroblasts and macro-
phages start to produce growth factors and cytokines, such as
PDGF, IL1b, TGFb, CXCL12 and matrix metalloproteases (MMPs)
which may lead to a highly proliferative and invasive behavior of
CSCs [70–72]. These data may suggest that tumors containing a
Fig. 2. The cells growing under sphere forming conditions are enriched for tumorigenic and radioresistant cell populations. (A) Prostate cancer cells DU145 and LNCaP are
more radioresistant when growing under 3D sphere-forming culture condition; ⁄p value <0.05. (B) Spherogenic potential of prostate cancer cells are inhibited if the PI3K/AKT
pathway and CXCR4 chemokine receptor signaling are blocked. DU145 cells were plated in 96 well low-attachment plates at 100 cells per well and the spheres were grown in
serum-free MEBM medium supplemented with 4 lg/mL insulin, B27, 20 ng/mL epidermal growth factor EGF, 20 ng/mL basic ﬁbroblast growth factor FGF. Spheres were
analyzed after 7 days as described earlier [163,164]. The CXCR4 chemokine receptor pathway was blocked with anti-CXCR4 and anti-SDF1a neutralizing antibody or activated
with CXCR4 ligand SDF1a. PI3K/AKT pathway was inhibited by NVP-BEZ235 inhibitor. The cells were imaged with an Acumen eX3 microplate cytometer and spheres were
detected using image analysis software. The spheres were discriminated from cell debris using a Gaussian ﬁlter. The large spheres outlined in red were included in the
analysis. (C) The radioresistant prostate cancer cells have high surface expression of CXCR4. (D) CXCR4 is more strongly expressed in prostate tumor cells than in the
corresponding normal epithelial tissues.
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radiotherapy schedules. Indeed, in a subset of tumors, hyperfrac-
tionated accelerated radiotherapy results in improved treatment
efﬁcacy, as shown in randomized trials in HNSCC and non-small
cell lung cancer (NSCLC) patients [73,74].
Analogous to differentiated somatic cells, which can be reset to
pluripotent cells by the process of induced dedifferentiation, non-
CSC tumor cells can be reprogrammed under ‘‘induced conditions.’’
Different stimuli coming from the microenvironmental niche and
anti-cancer therapies can trigger cancer cell reprogramming,
which results in the generation of induced CSC (iCSC) cell popula-
tion from non-CSC tumor cells [66,75]. There is growing evidence
for the possibility of dedifferentiation of non-CSCs by experimental
manipulations, such as overexpression of oncogenes (e.g. NANOG,
hTERT, OCT4), exposure to inﬂammatory cytokines (e.g. IL-6, IL-
1b, TNFa), and experimentally induced EMT by culturing the cells
under hypoxic conditions [39,76–82]. Factors contributing to the
phenotypical and functional diversity of CSCs are schematically
summarized in Fig. 3.
Finally, the multiplicity of the microenvironmental conditions
can affect CSC properties and contribute to CSC heterogeneity
within a tumor that will be discussed in the next paragraph.Microenvironment and cancer stem cell phenotype
The microenvironmental conditions can affect CSC properties
and contribute to CSC heterogeneity within a tumor. Status and
behavior of normal stem cells are determined by the local spacio-
temporal environment. Unique but dynamic niches play an essen-
tial role in the survival and maintenance of stemness regulating
the balance between homeostasis of the stem cell pool and the
induction of proliferation and differentiation processes [83]. The
dynamic behavior of the tumor microenvironment might deter-
mine phenotypic and functional properties of normal stem cells
transforming them into the malignant cells and contributing to
cancer development and metastatic spread of tumor cells from
the site of their origin [84–86]. Modulators in this scenario are
ECM compounds, stromal cell components including vascular ele-
ments as well as secreted para- and autocrine factors, such as bone
morphogenic proteins (BMPs) and Wnt proteins. Alterations in the
micromilieu conditions, i.e. in extracellular pH, oxygen partial
pressure and ion strength, which have been intensively studied
in radiobiology and radiotherapy over the past decades, also con-
tribute to stem cell regulation. The maintenance of CSCs may be
governed by the distinct microenvironmental niches at different
Fig. 3. The factors contributing to the phenotypic and functional diversity of CSC populations. CSC subsets vary from patient to patient due to genetic and epigenetic
differences. Heterogenic CSCs contribute to intratumor heterogeneity by establishing distinct clones within an individual tumor. Within tumor mass, CSC populations are
enriched in speciﬁc anatomic locations deﬁned by various factors such as speciﬁc paracrine and autocrine signaling, direct contact with surrounding stromal ﬁbroblasts,
immune cells, endothelial cells and components of the ECM (e.g. ﬁbronectin, laminin, proteoglycans and collagen ﬁbers) as well as gas and nutrient supply, and tissue
acidiﬁcation and bioenergetic status. The various microenvironmental inﬂuences, including oxygen tension and growth factors and cytokines, such as PDGF, IL1b, TGF b,
CXCL12 may regulate CSC properties, such as differentiation, self-renewal, invasiveness and tumorigenicity and contribute to CSC reprogramming.
384 Discovery of cancer stem cell radioresistancestages of tumor progression. However at the same time CSCs may
also directly contribute to the plasticity of their microenvironment
by the production of growth factors and chemokines such as VEGF,
TGFb, CXCL12, and by direct transdifferentiation into the cell lin-
eages other than the lineages of tumor cells [86–88].
The discovery and progress in the characterization of normal
stem cell niches have implications to the cancer stem cell concept.
Microenvironmental constraints may indeed affect the cancer stem
cell phenotype and biomarker expression, but in parallel also mod-
ulate the cancer cells’ susceptibility to treatment such as cell-
matrix interactions or oxygen availability [89,90]. Brain cancers
have been studied most intensively in this context and the inter-
play between neural cancer cells with stem cell characteristics
and the tumor microenviroment has turned out and claimed to
be the deadly teamwork [91]. Today, it is well accepted that cancer
stemness relates to a complex and heterogeneous malignant social
network [92], and it is assumed that cancer cells with stemness
potential are not ubiquitously distributed. Based on experimental
data, there are three potential niches discussed for the mainte-
nance or regeneration of CSCs with their exclusive tumor-propa-
gating potential: (A) a perivascular niche consisting of a
microanatomical vascular unit dominated by the interaction of
cancer cells with developing vascular structures. Within this niche
the proliferating endothelial cells, extracellular matrix as well as
various cellular partners, such as pericytes and macrophages can
affect the cancer cells’ phenotype and behavior by the release of
autocrine and paracrine biomodulators [91,93–97]. (B) An invasive
niche, where putative CSC subpopulations may undergo epithelial-
mesenchymal transition (EMT) assuming that only the ﬁttest can-
cer (stem) cells can adapt and survive migration, invasion and
extravasation processes and settle in the metastatic niche of a dis-
tant organ [98–101]. The invasive niche may indeed overlap with
the perivascular niche. And last but not least, (C) a hypoxic niche,
which considers the fact that adult normal stem cells are localized
in low oxygenated areas triggered by the local oxygen concentra-tion [3,91,97,102,103] and accommodates the ﬁnding that, similar
to normal stem cells, cancer cells in chronically hypoxic areas are
often cell cycle arrested and more resistant to therapy.
Hypoxia is a fundamental pathophysiological phenomenon
strongly associated with the development and aggressiveness of
various solid malignancies and also implicated in radio- and che-
moresistance [3]. Recent data provide a link between oxygen sup-
ply status, regulation of EMT phenotype and CSCs via the signaling
pathway of hypoxia inducible transcription factors (HIF) [104–
109]. HIFs (in particular HIF1a) are the master transcription factors
whose dysregulation contributes to an enhanced glycolytic ﬂux.
The cancer cell’s capacity to switch between oxidative phosphory-
lation and aerobic glycolysis and use the alternative substrate as
fuel for energy production may result in metabolic reprogramming
of CSCs [110–113]. The phenotype switching driven by the com-
plex miroenvironmental stimuli makes it difﬁcult to target CSCs
cells on one hand but opens a therapeutic window on the other
hand [112,114–118]. Tumor microenvironment and tumor cell
metabolism thus remain one of the central challenges for curative
treatment and to eradicate putative CSCs.Conclusion
In conclusion, many tumors contain heterogeneous CSC popula-
tions which can evolve resistance against cytotoxic treatments due
to various intrinsic mechanisms, extrinsic stimuli, epigenetic
changes and mutational alterations. A highly dynamic nature of
the intrinsic and extrinsic determinants of radioresistance along
with CSC plasticity and heterogeneity in the pathophysiological
heterologous environment make CSC population(s) a target that
may be hard to treat. Controlling the phenotypical and functional
properties of CSCs during radiation therapy is ultimative for opti-
mization and individualization of treatment strategy. Genomics,
proteomics and high-throughput studies validated by functional
C. Peitzsch et al. / Radiotherapy and Oncology 108 (2013) 378–387 385radiobiological assays and clinical observations are expected to
provide more information about new CSC-associated biomarkers
and CSC-targeted therapies in order to enhance the efﬁcacy of radi-
ation treatment and provide more tailored therapy for cancer
patients.
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